Lisata Jumps 17% on Marea Acquisition and $225M Financing
LSTA sits 72% above its 52-week low of $0.988 on elevated volume (9.9× avg).
Summary
Lisata Therapeutics shares surged 17% to $1.72 after announcing the acquisition of Marea Therapeutics and a concurrent $225 million private placement. The deal brings two antibody therapies, MAR001/005 and MAR002, with topline data expected in Q4 2027. This follows the collapse of the Kuva Labs merger in July and a 72% workforce reduction in August, making this a pivotal turnaround move. The financing provides runway to advance the newly acquired pipeline, though the company remains down 12% year-to-date. Investors are reacting positively to the strategic pivot and capital infusion.
At the time of this announcement, LSTA was trading at $1.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.3M. The 52-week trading range was $0.99 to $5.07. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.